Psychedelics Capital Moves: Beckley Waves Raises $3.3M, Clearmind's $2.25M Public Offering

Beckley Waves: $3.3 Million Round To Expand Safe & Legal Access To Psychedelic Therapies

Beckley Waves, a U.K.-based venture studio co-founded by "Queen of Psychedelics" Amanda Feilding with angel investors like FJ Labs, Courtney & Carter Reum, Joanne Wilson and actress Rosamund Pike, recently closed a $3.3 million (+10% than original target) funding round, saying that investors’ interest in care delivery and expanded access “marks the end of the ‘psychedelic winter’.”

Participants in this latest round include several family and VC mission-aligned offices such as the Joe & Sandy Samberg Foundation, Satori Neuro, Bridge Builders Collaborative, Evolve Ventures and Foundation, 1440 Foundation, Austin Hearst and Asia Agnelli. 

Feilding says that as public interest grows around psychedelics’ benefits, it is now “crucially important” to work on scaling up safe and legal access to them.

“Beckley Waves already has an impressive track record of founding and investing in startups that are building the care-delivery infrastructure, and this new funding gives us the resources to continue this important work,” she said. The co-founded Beckley Retreats, the Beckley Academy and The Trip Report are examples of such work.

The funding will allow Beckley Waves to fund catalytic strategic investments into selected early-stage teams, to support and guide them toward successful seed rounds.

Israeli Biotech’s Public Offering

Clearmind Medicine CMND is pricing its U.S.-only public offering, with gross proceeds expected at approximately $2.25 million and closing on Sept.18. Clearmind focuses on the discovery and development of novel psychedelic-derived therapeutics for major undertreated health conditions with a focus on alcohol use disorder.

The offering consists of 7,500,000 common shares and pre-funded warrants, and 7,500,000 common warrants. Common warrants are immediately exercisable, with a five-year expiration date from issuance and an exercise price of $0.30 per common share. 

Each common share (or replacing pre-funded warrant) is sold together with one common warrant at a combined purchase unit price of $0.30, but will be issued separately. These common warrants and pre-funded warrants will not be listed on any exchange.

Clearmind retained Aegis Capital as its exclusive placement agent and filed a registration statement on Form F-1 with the U.S. SEC, which declared it effective as of Sept. 14, 2023. The offering does not extend to Canada.

Ready for Benzinga's Cannabis Capital Conference? Come join us at the 17th edition of our biannual, crowd-puller event where deals get done, this Sept 27-28. Get your tickets today and secure your spot at the epicenter of cannabis investment and branding!

Photo: Benzinga edit with photo by PublicDomainPictures and janjf93 on Pixabay.